Loading stock data…
Candel Therapeutics (CADL)
$12.60-0.18 (-1.41%)
Market ClosedLast close Sep 8
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Candel Therapeutics, Inc. in the Healthcare sector is trading at $12.60 with a market capitalization of $591M. Wall Street consensus targets $21.00 (8 analysts), implying a +66.7% move over the next 12 months. The stock is currently near its 52-week high of $14.00, remaining 70.5% above its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +66.7% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$16.26M↓ | -$15.66M↓ | -$13.21M↓ | -$11.18M↓ | -$8.13M |
| Net Income | -$8.86M↑ | -$29.50M↓ | -$11.27M↓ | -$4.80M↓ | $7.38M |
Peer Comparison
JNJUNHPFE
Fundamentals
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients. It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Phase 2a clinical trials for the...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$590.92M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-39.43%
Volume
Today's trading volume
1.00M
Recent News
Candel Therapeutics (CADL) Is Up 5.4% After Steep Q2 Loss Widening Has The Bull Case Changed?
Candel Therapeutics, Inc. reported second-quarter 2026 results showing a net loss of US$38.91 million, up sharply from US$4.8 million a year earlier, with basic and diluted loss per share from continuing operations of US$0.52 versus US$0.09. For the first half of 2026, the company moved from net income of US$2.58 million a year ago to a net loss of US$47.77 million, highlighting a pronounced reversal in its recent financial performance. Next, we will examine how this sharp widening of losses...
Candel Therapeutics (CADL) Faces Bigger Losses As Its Valuation Still Looks Pricey
Candel Therapeutics (CADL) drew attention after reporting second quarter 2026 results that showed a net loss of US$38.91 million, compared with US$4.8 million a year earlier, indicating increased operating pressures. See our latest analysis for Candel Therapeutics. The latest earnings release landed alongside sharp share price gains for Candel Therapeutics, with a 1-day share price return of 12.03% and a 90-day share price return of 70.24%. The 3-year total shareholder return is also very...
CADL Rises As Biotech Eyes First Commercial Product in 2027 — CEO Points To ‘Meaningful Execution’ Toward BLA Submission In Q4
If the FDA approves aglatimagene besadenovec in the treatment of certain patients with prostate cancer, it would mark the company’s first commercial product.
CADL Stock In Focus As Candel Nears Year-End BLA Filing For Prostate Cancer Drug — Eyes $10–$16B Opportunity
Shares of Candel have drawn rising attention as the company advances its experimental immunotherapy, known as CAN-2409 or aglatimagene, toward potential approval in localized prostate cancer.
Candel Therapeutics Eyes 2026 Prostate Cancer Filing as Lung Study Ramps Up
Candel Therapeutics (NASDAQ:CADL) is advancing two off-the-shelf viral immunotherapy candidates designed for local administration intended to generate systemic immune responses against tumors, Chief Scientific Officer Francesca Barone said at the Canaccord Genuity Growth Conference in Boston. The c